We are pleased to announce the completion of patient enrollment in MS-DETECT (NCT05816122), an international study supported by Sanofi.

The study evaluates MSCopilot® Detect, our next-generation Software as a Medical Device (SaMD) designed for real-world monitoring of disease progression in Multiple Sclerosis (MS).

336 patients enrolled across more than 35 sites in 7 countries: US, Canada, France, Germany, Spain, Italy, and Denmark

Top-line results are expected in Q3 2027

An initial presentation of the interim data could be given at ECTRIMS 2025.

Check out our Press releases for all the details.